SHARE-BASED PAYMENTS - Schedule of Share-based Compensation, Restricted Stock, Restricted Stock Units Activity and SAR's (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended |
Mar. 31, 2023 | Mar. 31, 2022 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | | |
Share-based Payment Arrangement, Expense | $ 1,186 | $ 862 |
Equity Option | | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | | |
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share) | $ 4.12 | |
Nonvested, weighted average grant date fair value, end of period (in dollars per share) | $ 3.97 | |
Employee Stock Option | | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | | |
Share-based Payment Arrangement, Expense | $ 106 | 32 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | | |
Unrecognized Compensation Costs Related To Unvested Stock Options | 510 | |
Restricted Stock Units (RSUs) | | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | | |
Share-based Payment Arrangement, Expense | $ 644 | 484 |
Restricted Stock Units (RSUs) | Equity Option | | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] | | |
Number of nonvested shares, beginning of period (in shares) | 747,425 | |
Granted, nonvested, number of shares (in shares) | 450,232 | |
Vested, number of shares (in shares) | (448,883) | |
Forfeited, number of shares (in shares) | 0 | |
Number of nonvested shares, end of period (in shares) | 748,774 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | | |
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share) | $ 4.77 | |
Granted, nonvested, weighted average grant date fair value (in dollars per share) | 7.36 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | 0 | |
Vested, weighted average grant date fair value (in dollars per share) | 4.24 | |
Nonvested, weighted average grant date fair value, end of period (in dollars per share) | $ 6.64 | |
Stock Appreciation Rights (SARs) | | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | | |
Share-based Payment Arrangement, Expense | $ 436 | $ 346 |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] | | |
Number of nonvested shares, beginning of period (in shares) | 2,452,768 | |
Granted, nonvested, number of shares (in shares) | 308,333 | |
Exercised, number of shares (in shares) | 0 | |
Forfeited, number of shares (in shares) | (5,554) | |
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations | 0 | |
Number of nonvested shares, end of period (in shares) | 2,755,547 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | | |
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share) | $ 4.07 | |
Granted, nonvested, weighted average grant date fair value (in dollars per share) | 7.36 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Exercise Price | 0 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | 6.47 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expired, Weighted Average Grant Date Fair | 0 | |
Nonvested, weighted average grant date fair value, end of period (in dollars per share) | $ 4.43 | |
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Number | 1,092,143 | |
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Exercise Price | $ 2.92 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms | 2 years 1 month 13 days | |
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Remaining Contractual Term | 9 months 21 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding | $ 4,413 | |
Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Aggregate Intrinsic Value | $ 2,905 | |
Stock Appreciation Rights (SARs) | Equity Option | | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] | | |
Number of nonvested shares, beginning of period (in shares) | 1,360,625 | |
Granted, nonvested, number of shares (in shares) | 308,333 | |
Vested, number of shares (in shares) | 0 | |
Forfeited, number of shares (in shares) | (5,554) | |
Number of nonvested shares, end of period (in shares) | 1,663,404 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | | |
Nonvested, weighted average grant date fair value, beginning of period (in dollars per share) | $ 2.81 | |
Granted, nonvested, weighted average grant date fair value (in dollars per share) | 3.45 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | 5.20 | |
Vested, weighted average grant date fair value (in dollars per share) | 0 | |
Nonvested, weighted average grant date fair value, end of period (in dollars per share) | $ 2.92 | |